Question explored with the scientific record
Conversation so far
- 1 What is the risk benefit analysis of an older child getting and hpv-9 vaccine, and what is the proven benefit of taking multiple doses over just one dose
- 2 If multiple doses are mainly immunologic, is one dose ever enough?
Answered on this page ↓
If multiple doses are mainly immunologic, is one dose ever enough?
The evidence for one dose being enough for HPV-9 is growing but still rests on surrogate endpoints, not cancer outcomes.
The strongest direct evidence comes from a 2024 systematic review and meta-analysis that pooled data from five observational studies across India, Mongolia, Costa Rica, Scotland, and Fiji [1]. It found that one-dose HPV vaccination may offer protection against HPV DNA similar to multi-dose regimens, but the authors flagged high heterogeneity and susceptibility to outliers and publication bias [1]. A 2020 Italian cohort study of 11,773 women found a similar adjusted odds ratio for abnormal cytology with one dose (0.52) as with two or three doses, though the one-dose group had only 15 abnormal results out of 212 vaccinated women [2].
A 2025 systematic review reported mixed evidence: one large Australian real-world study found one dose comparable to two or three doses, while other studies suggested lower protection [3]. The same review noted that vaccine effectiveness against CIN3 drops from 97% in the 12-13 age cohort to 39% in the 16-18 cohort, regardless of dose number [3]. A 2024 Indian prospective cohort of 17,000 women found no significant difference in protection between 1-dose, 2-dose, and 3-dose regimens after up to 12 years of follow-up [5].
The immunologic argument for multiple doses is that antibody levels peak after the second dose and remain higher at three years than after a single dose [4]. But no trial in this retrieval directly compares cancer rates after one dose versus three doses. The dosing schedule was set based on antibody levels, a surrogate endpoint, not on hard clinical outcomes.
My call: the evidence supports that one dose provides meaningful protection, likely comparable to multiple doses for preventing HPV infection and precancerous lesions, but the data is observational and heterogeneous. Confidence: moderate that one dose is sufficient for protection against HPV infection and precancer; low for protection against cancer itself, which has not been directly studied.
Sources used 5
-
Efficacy of single-dose HPV vaccine over no vaccination and standard multiple dose regimen: a systematic review and meta-analysis of available evidence
One-dose HPV vaccination may offer protection against HPV DNA similar to multi-dose regimens, potentially enabling low-resource vaccination strategies, but evidence is highly heterogeneous and susceptible to outliers and publication bias.
DOI: 10.61505/evidence.2024.2.2.71 -
Human papillomavirus vaccine effectiveness within a cervical cancer screening programme: cohort study
A retrospective cohort study in Ferrara Province, Italy, linked vaccination and cervical screening registries to show that receiving one or more HPV vaccine doses substantially reduced the risk of cytological abnormalities detected during organized screening, with about a 50% re…
DOI: 10.1111/1471-0528.16429 -
The Impact of Prophylactic HPV Vaccination on the Incidence of High-Grade Cervical Intraepithelial Neoplasia (CIN2/CIN3): A Systematic Review
This systematic review finds HPV vaccination provides substantial protection against cervical precancer/cancer, with evidence for one-dose schedules, cross-protection, and reduced effectiveness with older vaccination; findings are promising but mixed and do not challenge the ove…
DOI: 10.70070/kjmnzx32 -
Immunogenicity and duration of antibodies after vaccination with a two-dose series of the nine-valent human papillomavirus vaccine among Alaska Native children: a prospective cohort study
After two-dose 9vHPV vaccination in Alaska Native children, more than 90% remained seropositive for all nine vaccine types at three years; one-year seropositivity was ≥95% for all types.
DOI: 10.1186/s12879-025-10961-z -
Literature Review: HPV Vaccine Development Over Time
Traces HPV vaccine development, efficacy across bivalent, quadrivalent, and nonavalent vaccines, dosing strategies (including emerging one-dose evidence), and policy implications with emphasis on Indonesia's immunization program.
DOI: 10.54543/kesans.v4i9.370